We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Omeros Corp is a United States-based biopharmaceutical company. Its goal is to research, develop, and commercialize small-molecule and protein therapeutics targeting inflammation, coagulopathies, and disorders of the central nervous system. The company owns Omidria (phenylephrine and ketorolac injec... Omeros Corp is a United States-based biopharmaceutical company. Its goal is to research, develop, and commercialize small-molecule and protein therapeutics targeting inflammation, coagulopathies, and disorders of the central nervous system. The company owns Omidria (phenylephrine and ketorolac injection), approved by the U.S. Food and Drug Administration and launched in the U.S. for use during cataract surgery and intraocular lens replacement. Its product pipeline is focused on complement-associated thrombotic microangiopathies; complement-mediated glomerulonephropathies; Huntington's disease and cognitive impairment; and addictive and compulsive disorders. Show more
-- Presentations Highlight Progress in Late-Stage Development of Lead MASP-3 Inhibitor Zaltenibart -- Omeros Corporation (Nasdaq: OMER) today announced that two abstracts directed to zaltenibart...
Omeros Corporation (Nasdaq: OMER) today announced an update on its progress toward planned resubmission of its biologics license application (βBLAβ) for narsoplimab, the companyβs first-in-class...
β Conference Call Today at 4:30 p.m. ET Omeros Corporation (Nasdaq: OMER) today announced recent highlights and developments as well as financial results for the third quarter ended September 30...
Omeros Corporation (NASDAQ: OMER), today announced that the company will issue its financial results for the quarter ended September 30, 2024, on Wednesday, November 13, 2024, after the market...
-- Phase 3 Studies on the Horizon in both PNH and C3G -- Omeros Corporation today announced that zaltenibart (OMS906) has received rare pediatric disease designation from the U.S. Food and Drug...
β Conference Call Today at 4:30 p.m. ET Omeros Corporation (Nasdaq: OMER), a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.82 | -6.90235690236 | 11.88 | 12.49 | 11.01 | 1038035 | 11.91715074 | CS |
4 | 6.84 | 162.085308057 | 4.22 | 12.49 | 4.175 | 1723279 | 8.12962835 | CS |
12 | 7.51 | 211.549295775 | 3.55 | 12.49 | 3.55 | 702229 | 7.25939266 | CS |
26 | 7.66 | 225.294117647 | 3.4 | 12.49 | 3.3901 | 523781 | 6.15020072 | CS |
52 | 8.84 | 398.198198198 | 2.22 | 12.49 | 2.22 | 528335 | 4.85008518 | CS |
156 | 3.92 | 54.9019607843 | 7.14 | 12.49 | 0.92 | 691710 | 4.3595088 | CS |
260 | -3.4 | -23.5131396957 | 14.46 | 25.49 | 0.92 | 756629 | 8.52975629 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions